MedTrace Logo

The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark

NCT00479973 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2007-11-20

No results posted yet for this study

Summary

Introduction: According to the World Health Organization (WHO), approximately 150 million people worldwide have type 2 diabetes. Common and cassia cinnamon have been reported to have anti-diabetic and lipid-lowering effects.

Objective: To determine if the combination common and cassia cinnamon product Cinnamonforce™ (Cinnamomum verum and C. aromaticum) reduces fasting blood glucose, insulin, glycosylated hemoglobin (HA1C), triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol levels in people with type 2 diabetes.

Methodology: Seventy (70) type 2 diabetic participants will be randomized to receive either 140 mg of Cinnamonforce twice daily or placebo over 12 weeks. Physical and laboratory measurements will be taken at baseline, 2 weeks, 4 weeks, 8 weeks and at the end of the trial, 13 weeks.

Results: The differences in the measurements obtained from the group receiving Cinnamonforce and the placebo group will be analyzed and discussed.

Conditions

Interventions

DIETARY_SUPPLEMENT

Cinnamonforce

Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule. 2 capsules after the two largest meals of the day

DIETARY_SUPPLEMENT

Placebo

Placebo. 2 capsules after the two largest meals of the day

Sponsors & Collaborators

  • The Canadian College of Naturopathic Medicine

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Rowena Ridout, MD · UHN

  • Jean-Jacques Dugoua, ND PhD(cand) · University of Toronto

  • Gideon Koren, MD · University Toronto

  • Tom Einarson, PhD · University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Completion
2008-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00479973 on ClinicalTrials.gov